Paul R. Yarnold

MedicinePsychologyMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)”.

Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)

EClinicalMedicine(2020)10.1016/j.eclinm.2020.100693

N/A

0.312DataRank · unranked

7 citations

Shamia Hoque, Nancy F. Olivieri, Matthew A. Taylor, David M. Aboulafia, Courtney Lubaczewski +29 more

Individual meropenem epithelial lining fluid and plasma PK/PD target attainment

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00727-23

N/A

0.312DataRank · unranked

7 citations

Paul R. Yarnold, Marc H. Scheetz, Michael Neely, Mengjia Kang, Helen K. Donnelly +10 more

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

The Oncologist(2021)10.1002/onco.13713

N/A

0DataRank · unranked

2 citations

Sumimasa Nagai, Andrew C. Bennett, Shamia Hoque, Chadi Nabhan, Martin W. Schoen +18 more

Iohexol-measured glomerular filtration rate and urinary biomarker changes between vancomycin and vancomycin plus piperacillin-tazobactam in a translational rat model

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.09.532007

N/A

0DataRank · unranked

1 citations

Gwendolyn Pais, Sylwia Marianski, Kimberly Valdez, Emily Lesnicki, Erin F. Barreto +4 more

Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.00102-25

N/A

0DataRank · unranked

1 citations

Monika Żurawska-Kliś, Emma Harlan, Marc H. Scheetz, MIchael N. Neely, Paul R. Yarnold +15 more

Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.01766-25

N/A

0DataRank · unranked

1 citations

Marta Zurawska, Adrian Valadez, Emma Harlan, Marc H. Scheetz, Michael Neely +14 more

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions

The Lancet Oncology(2020)10.1016/s1470-2045(20)30485-x

N/A

0DataRank · unranked

30 citations

Martin W. Schoen, Shamia Hoque, Bartlett J. Witherspoon, David M. Aboulafia, Catherine S. Hwang +9 more

Pharmacokinetic-pharmacodynamic target attainment with continuous infusion piperacillin in patients admitted to the ICU with hospital-acquired pneumonia

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.01760-25

N/A

0DataRank · unranked

0 citations

Adrian Valadez, Emma Harlan, Ryan H. Williamson, Marc H. Scheetz, Michael Neely +14 more

Decision models to improve healthcare-associated C. difficile PCR test use in patients with community-acquired pneumonia

medRxiv(2020)10.1101/2020.08.25.20181925

N/A

0DataRank · unranked

0 citations

Caroline Jozefczyk, William J Moore, Paul R. Yarnold, Karolina Harkabuz, Sarah H. Sutton +5 more